125 related articles for article (PubMed ID: 38440976)
1. Development of erlotinib-loaded nanotransferosomal gel for the topical treatment of ductal carcinoma
Mangla B; Mittal P; Kumar P; Javed S; Ahsan W; Aggarwal G
Nanomedicine (Lond); 2024 Apr; 19(10):855-874. PubMed ID: 38440976
[TBL] [Abstract][Full Text] [Related]
2. Erlotinib complexation with randomly methylated
Erdoğar N; Akkın S; Varan G; Bilensoy E
Pharm Dev Technol; 2021 Sep; 26(7):797-806. PubMed ID: 34219578
[TBL] [Abstract][Full Text] [Related]
3. Non-small cell lung cancer combination therapy: Hyaluronic acid modified, epidermal growth factor receptor targeted, pH sensitive lipid-polymer hybrid nanoparticles for the delivery of erlotinib plus bevacizumab.
Pang J; Xing H; Sun Y; Feng S; Wang S
Biomed Pharmacother; 2020 May; 125():109861. PubMed ID: 32070872
[TBL] [Abstract][Full Text] [Related]
4. Improved oral bioavailability and therapeutic efficacy of erlotinib through molecular complexation with phospholipid.
Dora CP; Kushwah V; Katiyar SS; Kumar P; Pillay V; Suresh S; Jain S
Int J Pharm; 2017 Dec; 534(1-2):1-13. PubMed ID: 28970115
[TBL] [Abstract][Full Text] [Related]
5. Erlotinib-Valproic Acid Liquisolid Formulation: Evaluating Oral Bioavailability and Cytotoxicity in Erlotinib-Resistant Non-small Cell Lung Cancer Cells.
Patel K; Doddapaneni R; Patki M; Sekar V; Bagde A; Singh M
AAPS PharmSciTech; 2019 Mar; 20(3):135. PubMed ID: 30830506
[TBL] [Abstract][Full Text] [Related]
6. Oral Squamous Cell Carcinoma Cells with Acquired Resistance to Erlotinib Are Sensitive to Anti-Cancer Effect of Quercetin via Pyruvate Kinase M2 (PKM2).
Chan CY; Hong SC; Chang CM; Chen YH; Liao PC; Huang CY
Cells; 2023 Jan; 12(1):. PubMed ID: 36611972
[TBL] [Abstract][Full Text] [Related]
7. Potential of erlotinib cyclodextrin nanosponge complex to enhance solubility, dissolution rate, in vitro cytotoxicity and oral bioavailability.
Dora CP; Trotta F; Kushwah V; Devasari N; Singh C; Suresh S; Jain S
Carbohydr Polym; 2016 Feb; 137():339-349. PubMed ID: 26686138
[TBL] [Abstract][Full Text] [Related]
8. PEGylated polypeptide lipid nanocapsules to enhance the anticancer efficacy of erlotinib in non-small cell lung cancer.
Kim J; Ramasamy T; Choi JY; Kim ST; Youn YS; Choi HG; Yong CS; Kim JO
Colloids Surf B Biointerfaces; 2017 Feb; 150():393-401. PubMed ID: 27825759
[TBL] [Abstract][Full Text] [Related]
9. Paclitaxel and Erlotinib-co-loaded Solid Lipid Core Nanocapsules: Assessment of Physicochemical Characteristics and Cytotoxicity in Non-small Cell Lung Cancer.
Gupta B; Poudel BK; Regmi S; Pathak S; Ruttala HB; Gautam M; An GJ; Jeong JH; Choi HG; Yong CS; Kim JO
Pharm Res; 2018 Mar; 35(5):96. PubMed ID: 29536182
[TBL] [Abstract][Full Text] [Related]
10. Stability and Formulation of Erlotinib in Skin Creams.
Nguyen D; Secrétan PH; Cotteret C; Jacques-Gustave E; Greco C; Bodemer C; Schlatter J; Cisternino S
Molecules; 2022 Feb; 27(3):. PubMed ID: 35164335
[TBL] [Abstract][Full Text] [Related]
11. Vorinostat induces G2/M cell cycle arrest in breast cancer cells via upregulation of PTEN.
Alqosaibi AI; Abdel-Ghany S
Eur Rev Med Pharmacol Sci; 2023 Feb; 27(4):1503-1511. PubMed ID: 36876690
[TBL] [Abstract][Full Text] [Related]
12. Curcumin mediated down-regulation of α
Javadi S; Rostamizadeh K; Hejazi J; Parsa M; Fathi M
Phytother Res; 2018 Feb; 32(2):355-364. PubMed ID: 29168312
[TBL] [Abstract][Full Text] [Related]
13. RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in patients with untreated, EGFR-mutated, metastatic non-small cell lung cancer: Europe/United States subset analysis.
Ponce Aix S; Novello S; Garon EB; Nakagawa K; Nadal E; Moro-Sibilot D; Alonso Garcia M; Fabre E; Frimodt-Moller B; Zimmermann AH; Visseren-Grul CM; Reck M;
Cancer Treat Res Commun; 2021; 27():100378. PubMed ID: 33905962
[TBL] [Abstract][Full Text] [Related]
14. Kaempferol potentiates the sensitivity of pancreatic cancer cells to erlotinib via inhibition of the PI3K/AKT signaling pathway and epidermal growth factor receptor.
Zhang Z; Guo Y; Chen M; Chen F; Liu B; Shen C
Inflammopharmacology; 2021 Oct; 29(5):1587-1601. PubMed ID: 34322786
[TBL] [Abstract][Full Text] [Related]
15. Cyclodextrin modified erlotinib loaded PLGA nanoparticles for improved therapeutic efficacy against non-small cell lung cancer.
Vaidya B; Parvathaneni V; Kulkarni NS; Shukla SK; Damon JK; Sarode A; Kanabar D; Garcia JV; Mitragotri S; Muth A; Gupta V
Int J Biol Macromol; 2019 Feb; 122():338-347. PubMed ID: 30401652
[TBL] [Abstract][Full Text] [Related]
16. Antipsoriatic and Anti-inflammatory Studies of
Nimisha ; Rizvi DA; Fatima Z; Neema ; Kaur CD
Pharmacogn Mag; 2017 Oct; 13(Suppl 3):S587-S594. PubMed ID: 29142419
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of Pancreatic Cancer Therapy Efficacy by Type-1 Matrix Metalloproteinase-Functionalized Nanoparticles for the Selective Delivery of Gemcitabine and Erlotinib.
Yin N; Yu H; Zhang X; Lv X
Drug Des Devel Ther; 2020; 14():4465-4475. PubMed ID: 33122890
[TBL] [Abstract][Full Text] [Related]
18. RELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients with Untreated, Epidermal Growth Factor Receptor Mutation-Positive, Metastatic Non-Small-Cell Lung Cancer: Safety Profile and Manageability.
Nadal E; Horinouchi H; Shih JY; Nakagawa K; Reck M; Garon EB; Wei YF; Kollmeier J; Frimodt-Moller B; Barrett E; Lipkovich O; Visseren-Grul C; Novello S
Drug Saf; 2022 Jan; 45(1):45-64. PubMed ID: 34928484
[TBL] [Abstract][Full Text] [Related]
19. Erlotinib entrapped in cholesterol-depleting cyclodextrin nanoparticles shows improved antitumoral efficacy in 3D spheroid tumors of the lung and the liver.
Varan G; Akkın S; Demirtürk N; Benito JM; Bilensoy E
J Drug Target; 2021 Apr; 29(4):439-453. PubMed ID: 33210947
[TBL] [Abstract][Full Text] [Related]
20. Ramucirumab or placebo plus erlotinib in EGFR-mutated, metastatic non-small-cell lung cancer: East Asian subset of RELAY.
Nishio M; Seto T; Reck M; Garon EB; Chiu CH; Yoh K; Imamura F; Park K; Shih JY; Visseren-Grul C; Frimodt-Moller B; Zimmermann A; Homma G; Enatsu S; Nakagawa K;
Cancer Sci; 2020 Dec; 111(12):4510-4525. PubMed ID: 32954593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
